A financial model for an impact investment fund for the development of antibacterial treatments and diagnostics

  05 June 2020

This financial model was prepared as part of an overall project on setting up an impact investment fund to foster development of new antibacterial treatments. It can be used by any company, private or public investor to model cost, and risk of antibiotic development. It may also assist public entities and decision makers in calculating the possible amount and assessing the impact of instruments such as market entry rewards or milestone prizes to pull more investment into antibiotic research.

The model is not meant to provide advice on individual investment decisions.

Further reading: WHO
Author(s): WHO
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed